CAS: 10132-07-7; 4-Amino-2,6-Dichloropyrimidine

相似化合物

1244949-72-1 5305-59-9 32998-03-1

上下游产品

CAS号873-83-6 6-氨基尿嘧啶 | CAS号3764-01-0 2,4,6-三氯嘧啶 | CAS号91-66-7 N,N-二乙基苯胺 | CAS号7664-41-7 氨 | CAS号1075-39-4 6-CHLORO-N2,N2-... | CAS号53557-69-0 4-氨基-6-碘嘧啶 | CAS号3286-55-3 4-氨基-6-氯-2-甲氧基嘧啶 | CAS号3289-38-1 4-氨基-6-氯-2-二乙基氨基嘧啶 | CAS号1398507-08-8 4-(4-氨基-6-氯嘧啶-2... | CAS号101012-11-7 5-溴-2,6-二氯嘧啶-4-胺 | CAS号3549-05-1 6-氯-2-吗啉嘧啶-4-胺 | CAS号321328-97-6 2,6-DICHLORO-4-... | CAS号3289-39-2 6-CHLORO-2-(1-P... | CAS号156-83-2 2,4-二氨基-6-氯嘧啶

4-Amino-2,6-Dichloropyrimidine-5-Carboxylic Acid 以 水 用作溶剂,化学反应 4.0H,以27.6 G的收率获得4-氨基-2,6-二氯嘧啶
参考文献:一种4-氨基-2.6-二甲氧基嘧啶的合成方法
标题:一种4-氨基-2.6-二甲氧基嘧啶的合成方法
摘要:本发明公开了医药技术技术领域的一种4‑氨基‑2.6‑二甲氧基嘧啶的合成方法.该合成方法包括如下步骤:(1)氨解反应:将4,6‑二氯嘧啶‑5‑甲酸投入到氨水中进行氨解反应,得到4‑氨基‑6‑氯嘧啶‑5‑甲酸;(2)氯化反应:将步骤(1)制得的4‑氨基‑6‑氯嘧啶‑5‑甲酸溶于稀酸水,然后加入氯化试剂氯化得到4‑氨基‑2,6‑氯嘧啶‑5‑甲酸;(3)脱羧反应:在溶剂中,将步骤(2)中制得的4‑氨基‑2,6‑氯嘧啶‑5‑甲酸经高温脱羧得到4‑氨基‑2,6‑氯嘧啶;(4)甲氧化反应:将步骤(3)制得的4‑氨基‑2,6‑氯嘧啶投入甲氧基化试剂中,经甲氧化反应得到4‑氨基‑2.6‑二甲氧基嘧啶.本发明采用新的合成路线,避免了大量的含磷废水的产生,本发明所提供的方法绿色环保,社会效益明显.

专利信息

专利号:US-8895747-B2
优先权日:2009-07-27
标 题 :Method and substances for preparation of N-substituted pyridinium compounds
发明人：HEINDL DIETER; MAERZ HERIBERT; SCHMIDT AXEL
权利人:HEINDL DIETER; MAERZ HERIBERT; SCHMIDT AXEL; ROCHE DIAGNOSTICS OPERATIONS
摘要:Methods for the synthesis of N-substituted pyridinium compounds by using an N-heteroaryl substituted pyridinium salt (Zincke salt) and reacting it with a nucleophilic amine are provided. Novel purine-substituted pyridyl compounds, which may be useful reagents in the above reaction, are also disclosed.

专利号:JP-6038111-B2
优先权日:2014-12-27
标 题:2,6-Dichloro-8-iodo-7-deazapurine for the synthesis of polysubstituted 7-deazapurine derivatives

专利号:US-2013123498-A1
优先权日:2011-10-19
标 题 :Process for the preparation of etravirine and intermediates in the synthesis thereof
发明人：MAJER MAJA SEPELJ; KRIZMANIC IRENA; VRBANEC GORDANA
权利人:MAJER MAJA SEPELJ; KRIZMANIC IRENA; VRBANEC GORDANA
摘要:The present invention includes compounds of Formula 1 of the following structure: n n n n n n n n n n or salts thereof, wherein X is a halogen or a tosyl group. Processes for preparing the compounds of Formula 1 are disclosed in the patent application. The compounds of Formula 1 are useful as intermediates for preparation of Etravirine. The present invention is also directed toward processes for preparing Etravirine.

专利号:WO-2012170647-A1
优先权日:2011-06-09
标题 :Process for the preparation of etravirine and intermediates in the synthesis thereof
发明人：SEPELJ MAJER MAJA; KRIZMANIC IRENA; SEPAC DRAGAN
权利人:ASSIA CHEM IND LTD; TEVA PHARMA; SEPELJ MAJER MAJA; KRIZMANIC IRENA; SEPAC DRAGAN
摘要:The present patent application provides intermediates, e.g., 4-(6-(acetylamino)-2- chloropyrimidin-4-yloxy)-3,5-dimethylbenzonitrile, for preparing Etravirine or the salts of Etravirine, and processes for preparing Etravirine or its salts as disclosed in the specification herein. The application also provides processes for preparing 4-(6-(acetylamino)-2- chloropyrimidin-4-yloxy)-3,5-dimethylbenzonitrile.

专利号:EP-2342186-B1
优先权日:2009-06-22
标 题:Process for synthesis of etravirine
发明人：GURJAR MUKUND KESHAV; MAIKAP GOLAKCHANDRA SUDARSHAN; JOSHI SHASHIKANT GANGARAM; PARDESHI DEVISING RAMESHSING; KAMBLE MANGESH GORAKHANATH; MEHTA SAMIT SATISH
权利人:EMCURE PHARMACEUTICALS LTD

专利号:US-6472403-B2
优先权日:2000-01-20
标 题 :αV integrin receptor antagonists
发明人：DUGGAN MARK E; HALCZENKO WASYL; HUTCHINSON JOHN H; LI AIWEN; MEISSNER ROBERT S; PERKINS JAMES J; STEELE THOMAS G; WANG JIABING; PATANE MICHAEL A
权利人:MERCK & CO INC
摘要:The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.